Neurometabolic Diseases Lab

  • Increase font size
  • Default font size
  • Decrease font size
Home Lines of Research Publications
Title Filter     Display # 
# Article Title Hits
41 The absence of ABCD2 sensitizes mice to disruptions in lipid metabolism by dietary erucic acid. J Lipid Res. 2012 Jun;53(6):1071-9 592
42 Bezafibrate lowers very long-chain fatty acids in X-linked adrenoleukodystrophy fibroblasts by inhibiting fatty acid elongation. J Inherit Metab Dis (2012) 35:1137–1145. 597
43 Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: A paradigm for multifactorial neurodegenerative diseases? Biochim Biophys Acta. 2012 Sep;1822(9):1475-88. 699
44 JNK/ERK/FAK mediate promigratory actions of basic fibroblast growth factor in astrocytes via CCL2 and COX2. Neurosignals. 2012;20(2):86-102. 612
45 Amyloid Generation and Dysfunctional Immunoproteasome Activation with Disease Progression in Animal Model of Familial Alzheimer's Disease. Brain Pathol. 2012 Sep;22(5):636-653. 591
46 Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy. 2012 Mar 1;21(5):1062-77. 954
47 Neurochemistry and the non-motor aspects of PD. Neurobiol Dis. 2012 Jun;46(3):508-26. 504
48 Antioxidants Halt Axonal Degeneration in a Mouse Model of X-Adrenoleukodystrophy. ANN NEUROL 2011;70:84–92 833
49 Phylogenomic evidence for a myxococcal contribution to the mitochondrial fatty acid beta-oxidation.PLoS One. 2011;6(7):e21989. 701
50 Oxidative Damage Compromises Energy Metabolism in the Axonal Degeneration Mouse Model of X-Adrenoleukodystrophy. Antioxid Redox Signal. 2011 Oct 15;15(8):2095-107 1117
51 Invariant NKT cells in adrenoleukodystrophy patients and mice.J Neuroimmunol. 2010 Dec 15;229(1-2):204-11. 898
52 Staging anti-inflammatory therapy in Alzheimer's disease. Front Aging Neurosci. 2010 Oct 25;2:142. 860
53 Current and Future Pharmacological Treatment Strategies in X-Linked Adrenoleukodystrophy. MINI-SYMPOSIUM: X - Linked Adrenoleukodystrophy. Brain Pathol. 2010 Jul;20(4):845-56. 1238
54 Pathomechanisms Underlying X-Adrenoleukodystrophy: A Three-Hit Hypothesis. MINI-SYMPOSIUM: X - Linked Adrenoleukodystrophy. Brain Pathol. 2010 Jul;20(4):838-44. 958
55 General Aspects and Neuropathology of X-Linked Adrenoleukodystrophy. MINI-SYMPOSIUM: X - Linked Adrenoleukodystrophy. Brain Pathol. 2010 Jul;20(4):817-30. 1227
56 Schilder's disease a heterogenous group of disorders known as X-linked adrenoleukodystrophy. Foreword.. MINI-SYMPOSIUM: X - Linked Adrenoleukodystrophy. Brain Pathol. 2010 Jul;20(4):815-6. 945
57 Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Hum Mol Genet. 2010 May 15;19(10):2005-14. Epub 2010 Feb 23. 1118
58 PeroxisomeDB 2.0: an integrative view of the global peroxisomal metabolome. Nucleic Acids Res. 2010 Jan;38(Database issue):D800-5. 1901
59 Insulin-like Growth Factor-1 and Neurotrophin-3 Gene Therapy Prevents Motor Decline in an X-Linked Adrenoleukodystrophy Mouse Model. ANNALS OF NEUROLOGY. 66, 1, 117-122 (2009) 966
60 ABCD2 is abundant in adipose tissue and opposes the accumulation of dietary erucic acid (C22:1) in fat. J Lipid Res. 2010 Jan;51(1):162-8. 1404
Page 3 of 4

View My Stats